Mobile apps and other emerging technologies are providing personalized, real-time, data-driven support to help people make decisions about their diabetes management. 6, 7 These technologies, including smartphone apps, patient monitoring devices, tablets, personal digital assistants, and other wireless devices, are helping to create a new digital universe of tools for more precise and consistent management of diabetes for patients and their care teams. 6, 7 The Contour ® Plus ONE (Ascensia Diabetes Care, Parsippany, NJ, USA) is a new blood glucose monitoring system (BGMS) that features an easy-to-use, wirelessenabled blood glucose meter that links to a smart mobile device via Bluetooth ® connectivity. The new BGMS is also designed to sync with the Contour™ Diabetes app, which is available on smartphone or tablet and provides multiple functions, including displays of trends and test results as compared with targets; testing reminders; graphs of test results over a day or a longer period of time; sharing of reports; and review of fasting, preprandial, postprandial, and overall results on a daily graph. The BGMS utilizes currently available Contour ® Plus test strips (Ascensia Diabetes Care), which contain the flavin adenine dinucleotide-glucose dehydrogenase (FAD-GDH) enzyme and a proprietary electron mediator.
People with diabetes use blood glucose test results obtained from SMBG to make critical decisions about their treatment; it is therefore imperative that results are accurate to prevent nutritional and drug-dosing errors. 8 Guidelines provided by the International Organization for Standardization (ISO) are used to assess the accuracy of a BGMS. 9 The accuracy of the new BGMS was assessed in the laboratory and in clinical settings according to ISO 15197:2013 guidelines. In the first study, the analytical accuracy of the BGMS was examined in the laboratory based on ISO 15197:2013 Section 6.3 criteria. In the second study, the performance and ease of use of the new BGMS was assessed in a clinical setting by persons with diabetes according to ISO 15197:2013 Section 8 guidelines. The primary objective of the clinical study was to evaluate the performance of the system in the hands of subjects with diabetes using fingertip blood, based on ISO 15197:2013 Section 8 accuracy criteria. Additional objectives were to assess study staff-obtained fingertip, subjectobtained palm, and study staff-obtained venous results, and to obtain feedback from subjects on the ease of use of the BGMS and the User Guide instructions.
Methods
Laboratory Study: Analytical Accuracy (ISO 15197:2013 Section 6.3) To evaluate accuracy, study staff-obtained fingertip capillary blood samples from 100 subjects were tested using 3 test strip lots; each sample was tested in duplicate (N = 600). Two sets of 6 blood glucose meters were alternated between subjects. After every 10 subjects, a new vial of test strips was used; a total of 11 vials per lot were included in the study. The distribution of blood glucose concentrations of the 100 blood samples conformed to the ISO 15197:2013 requirement. Most samples (n = 88) were tested fresh from the finger without modification. However, contrived samples at the low and high ends of the distribution were obtained by allowing 8 This clinical trial was conducted at 2 sites and included both male and female subjects with type 1 or type 2 diabetes who were aged ≥18 years and had not used this BGMS previously. Before participating in capillary blood glucose testing, subjects stated that for ≥2 hours they had fasted, had not taken bolus insulin or oral diabetes medications, and had not vigorously exercised. Each subject's participation consisted of 1 study visit, except for 1 subject who was enrolled on one day and returned to the site the next day for study testing due to an adverse event of hypoglycemia on the day of enrollment. The protocol, informed consent forms, and all study documents were approved by an Institutional Review Board prior to study start, and each subject completed the informed consent process before participating in the study.
During the single study visit, prior to blood glucose testing, subjects were provided with the BGMS and the instructional materials (User Guide and Quick Reference Guide) and were given time to review the materials to learn how to use the system; no additional training was provided. Each subject performed a fingertip test for blood glucose on the BGMS. Within 5 minutes of the subject fingertip test, site staff collected blood from a separate fingertip lancing for the capillary YSI reference assay. Subjects then performed a palm alternate site test for blood glucose on the BGMS. Immediately after the palm test, site staff performed a blood glucose test with the subject's fingertip blood. Finally, site staff performed a venipuncture on each subject, and that blood was used to complete 1 meter test, a hematocrit measurement, and a venous YSI reference assay. Three test strip lots were used in the study, with each subject randomized to 1 lot. The test strip lots were provided to the investigator by the study sponsor. All BGMS results were compared with YSI reference results.
Accuracy of the BGMS was evaluated based on ISO 15197:2013 Section 8 accuracy criteria 9 (ie, within ±15 mg/dl [±0.8 mmol/L] or ±15% of the reference result for samples with blood glucose concentrations <100 mg/dl [<5.6 mmol/L] and ≥100 mg/dl [≥5.6 mmol/L], respectively). Regression analyses were performed to compare BGMS results with YSI reference results. ParkesConsensus Error Grid analyses 10 were performed to evaluate results based on the clinical significance of differences between BGMS results and YSI reference values, and radar plots were constructed to compare BGMS results with YSI reference results.
Subjects also completed a questionnaire on the ease of use of the BGMS and the User Guide instructions; possible responses ranged between 1 (strongly disagree) and 5 (strongly agree). Subjects completed a second questionnaire on diabetes management behaviors; possible responses were 0 (no answer) and 1 (strongly disagree) to 5 (strongly agree). The questionnaires are provided in the Supplemental Material. Adverse events were monitored throughout the trial.
Results

Laboratory Study: Analytical Accuracy (ISO 15197:2013 Section 6.3)
In total, 600 BGMS results were obtained by testing 100 fingertip capillary blood samples in duplicate using 3 lots of test strips. The range of plasma blood glucose concentrations was 37 mg/dl (2.1 mmol/L) to 526 mg/dl (29.2 mmol/L). The hematocrit range was 34.5% to 56.0%, which was within the approved hematocrit range for this product.
Analysis of BGMS results based on ISO 15197:2013 Section 6.3 accuracy criteria showed that 99.0% (594/600) of combined results for all 3 test strip lots were within ±15 mg/ dl (±0.8 mmol/L) or ±15% of the YSI reference results for samples with blood glucose concentrations <100 mg/dl (<5.6 mmol/L) or ≥100 mg/dl (≥5.6 mmol/L), respectively (Table 1) . Furthermore, 96.3% (578/600) of combined results for all 3 test strip lots were within ±10 mg/dl (±0.6 mmol/L) or ±10% of the YSI reference results for samples with blood glucose concentrations <100 mg/dl (<5.6 mmol/L) or ≥100 mg/dl (≥5.6 mmol/L), respectively (Table 1 ). An ad hoc analysis was conducted to determine the smallest error range that contained ≥95% of meter inaccuracies (ie, differences between meter results and YSI reference results), with the determination being that 95% of meter results had inaccuracies that were within 9.4 mg/ dl (0.5 mmol/L) or 9.4% of the YSI reference result. A plot of the differences of BGMS results from YSI reference results is shown in Figure 1A . A radar plot comparing BGMS results to YSI reference results is shown in Figure 1C . A radar plot is a new way to plot the differences between BGMS values and reference instrument values. The outer green circle (bolder line) represents ±15 mg/dl (±0.8 mmol/L) or ±15% error for samples with YSI blood glucose concentrations <100 mg/dl (<5.6 mmol/L) or ≥100 mg/dl (≥5.6 mmol/L), respectively. Points within this circle satisfy ISO 15197:2013 Section 6.3 accuracy criteria.
Clinical Trial: User Performance Evaluation (ISO 15197:2013 Section 8)
Subjects. A total of 134 subjects enrolled in the clinical trial and all subjects completed the trial. Mean (range) age was 54 (18-77) years; 47% of subjects had type 1 diabetes, 52% had type 2 diabetes, and 1% had diabetes of unknown type ( Table  2 ). The ratio of female to male subjects was balanced (52% female; 48% male). Most subjects (75%) reported that they self-test their blood glucose ≥2 times daily.
Subject-obtained capillary fingertip results were analyzed from 134 subjects for self-testing. Eight subjects did not have evaluable subject-obtained palm test results because the YSI blood glucose value was <70 mg/dL (n = 4) or the palm test was not performed (n = 4). Two subjects did not have evaluable study staff-obtained venous blood tests due to unsuccessful venipuncture.
The blood glucose concentrations of the subjects' blood samples, as measured by YSI, ranged from 44.3 mg/dl (2.5 mmol/L) to 474.5 mg/dl (26.3 mmol/L) for capillary (Table 3 ).
An ad hoc analysis was conducted to determine the smallest error range that contained ≥95% of meter inaccuracies (ie, differences between meter results and YSI reference results). Overall, 95% of results had inaccuracies that were within 8.5 mg/dl (0.5 mmol/L) or 8.5% of the YSI reference results for subject-obtained fingertip blood tests, within 8.6 mg/dl (0.5 mmol/L) or 8.6% of the YSI reference results for study staff-obtained fingertip blood tests, within 10.4 mg/dl (0.6 mmol/L) or 10.4% of the YSI reference results for subject-obtained palm blood tests, and within 6.3 mg/dl (0.3 mmol/L) or 6.3% of the YSI reference results for study staff-obtained venous blood tests.
A plot of the differences of subject-obtained capillary fingertip results from YSI reference results is shown in Figure 2A . Regression analysis demonstrated a strong correlation between BGMS results and YSI reference results. The adjusted R 2 value was 0.9848 for subject-obtained capillary fingertip results. The adjusted R 2 values for study staff-obtained fingertip, subject-obtained palm, and study staff-obtained venous results were 0.9864, 0.9697, and 0.9940, respectively.
Parkes-Consensus Error Grid analysis demonstrated that 100% (134/134) of subject-obtained capillary fingertip results were within Zone A ( Figure 2B ). All results (100%) were also within Zone A for study staff-obtained fingertip (134/134), subject-obtained palm (126/126), and study staffobtained venous (132/132) testing. A radar plot comparing subject-obtained capillary fingertip results to YSI reference results is shown in Figure 2C .
Subject questionnaires. Ease-of-use questionnaire responses demonstrated that most subjects "strongly agree," "agree," or are "neutral" that it is easy to do a fingerstick blood test with this meter (99.2%), the meter display is easy to see and read (98.5%), it is easy to understand the test results (100%), the instructions are easy to understand (96.3%), the instructions clearly explain how to run a test (97.8%), and the instructions clearly explain what to do if an error message is displayed by the meter (99.2%).
Diabetes management questionnaire responses demonstrated that the majority of subjects responded "strongly agree," "agree," or "neutral" that accuracy is important: (1) to help with their ability to manage their diabetes (100%), (2) to help with understanding how food or exercise affects low blood sugars (100%), (3) to help with preventing low blood sugars (100%), and (4) to help with using their results to gain better control of their diabetes (100%). In addition, 80.0% of subjects responded "strongly agree," "agree," or "neutral" that they use their current meters because their insurance companies cover the strips, and 86.5% of subjects responded "strongly agree," "agree," or "neutral" that they preferred the meter used in this study to their regular meters.
Safety. There were 4 mild, anticipated, non-device-related adverse events, all classified as hypoglycemia. All adverse events resolved prior to the subjects leaving the testing site.
Discussion
SMBG has been shown to lead to improved outcomes for persons with diabetes; thus, it is an important part of the selfmanagement of diabetes. 1, [3] [4] [5] Mobile apps can also help people manage their diabetes by providing useful information to guide their diabetes management decisions and by providing valuable data to their health care providers.
6,7 Treatment modification recommendations have been shown to be more effective in improving glycemic control when supplied by physicians with access to patient-provided SMBG data compared with recommendations initiated by physicians without SMBG data. 4 Various clinical benefits of using mobile apps for diabetes, including reductions in HbA1c levels, have been demonstrated in some studies; however, additional research is needed to provide further support for these benefits. [11] [12] [13] [14] Both the laboratory study and the clinical study described previously demonstrated the accuracy of the new BGMS that has been developed for use with currently available test strips that contain the FAD-GDH enzyme and a proprietary mediator. The BGMS was designed to wirelessly interact with the Contour™ Diabetes app on a smartphone or tablet.
The BGMS exceeded ISO 15197:2013 accuracy criteria in the laboratory study (Section 6.3) and in the clinical study when used by untrained subjects (Section 8). In the laboratory study, 99% of results with the BGMS met ISO 15197:2013 Section 6.3 accuracy criteria, and 96.3% of results were within 10 mg/dl or 10% of the YSI reference values. In the clinical study, ISO 15197:2013 Section 8 accuracy criteria were met by 99.2% of capillary fingertip, 99.2% of palm, and 100% of venous blood samples. Accuracy was similar whether the system was used by subjects who had never used this BGMS previously or by study staff.
In the clinical study, the BGMS also demonstrated ease of use in the hands of untrained subjects with diabetes. The majority of subjects rated the system as easy to use with respect to performing a fingertip blood test. The majority of subjects also felt that the meter display is easy to see and read and that the test results and user instructions are easy to understand. All subjects agreed on the importance of BGMS accuracy to help with managing their diabetes, understanding how food or exercise affects low blood sugars, preventing low blood sugars, and using their results to gain better control of their diabetes.
Conclusions
In conclusion, the analytical and clinical accuracy of the new BGMS as well as its ease of use in persons with diabetes were demonstrated by the results of these studies. 
